What is a capmatinib drug interaction?

Release date: 2024-08-09 15:57:34     Recommended: 136

Capmatinib is a targeted drug manufactured by Novartis for the treatment of patients with non-small cell lung cancer (NSCLC) with mutations in the MET gene. It stops the growth and spread of cancer cells by inhibiting the activity of MET kinase.

What is a capmatinib drug interaction?

Both physicians and patients should be concerned about drug interactions, which are summarized as follows according to clinical studies:

1. CYP3A inhibitors

When used in combination with strong CYP3A inhibitors, the drug exposure to capmatinib increases, which may lead to increased side effects. Patients should be closely monitored for response.

2. CYP3A inducers

Combination with strong or moderate CYP3A inducers reduces drug exposure to capmatinib and may reduce antitumor activity. Avoid concomitant use of capmatinib with CYP3A inducers.

Who is the special drug taker of capmatinib?

Before purchasing and using drugs, patients should know about the relevant matters related to the use of drugs in special populations, and the following are the instructions for the use of drugs in special people:

1. Pregnant women

There are no data on the use of capmatinib in pregnant women. Pregnant women should be informed of the potential risks to the fetus that the drug may pose to the fetus before taking the drug, and detailed counseling and risk assessment should be conducted.

2. Lactating females

Breastfeeding women should avoid breastfeeding during treatment with capmatinib and for one week after the last dose to avoid potential effects on the infant.

What are the precautions for capmatinib?

According to the drug leaflet, patients need to pay attention to the following important points when using this medicine:

1. Interstitial lung disease (ILD)/pneumonia

Patients should be monitored for new or worsening pulmonary symptoms, and capmatinib should be permanently discontinued if ILD or pneumonia is confirmed.

2. Hepatotoxicity

Liver function tests should be performed regularly to determine whether the drug needs to be discontinued, reduced, or permanently discontinued, depending on the severity of the adverse effects.

[Warm tips] Patients should also maintain a reasonable diet during the treatment of capmatinib. According to the needs of the body, patients should eat foods rich in protein and vitamins appropriately, and avoid spicy, greasy and other irritating foods.